General Information:

Id: 2,119
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Rattus norvegicus
male
article
Reference: Oelze M et al.(2006) Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 48: 677-684 [PMID: 16940222]

Interaction Information:

Comment Angiotensin II infusion caused endothelial dysfunction in male Wistar rats and increased vascular superoxide.
Formal Description
Interaction-ID: 17327

gene/protein

Angiotensin II

increases_activity of

Comment Angiotensin II infusion caused endothelial dysfunction in male Wistar rats and increased vascular superoxide.
Formal Description
Interaction-ID: 17328

gene/protein

Angiotensin II

increases_quantity of

drug/chemical compound

O2-

Comment Ang II treatment caused a marked impairment of the NO/cGMP signaling assessed by the phosphorylation of the vasodilator stimulated phosphoprotein.
Formal Description
Interaction-ID: 17329

gene/protein

Angiotensin II

decreases_phosphorylation of

gene/protein

VASP

Comment Ang II treatment caused a marked impairment of the NO/cGMP signaling assessed by the phosphorylation of the vasodilator stimulated phosphoprotein.
Formal Description
Interaction-ID: 17330

gene/protein

Angiotensin II

decreases_activity of

process

NO/cGMP-mediated signaling

Comment In vivo treatment with nebivolol markedly improved endothelial dysfunction and increased P-VASP levels in Ang II-treated animals, while having no effects on these parameters in control animals. Metoprolol had no significant effects on these parameters.
Formal Description
Interaction-ID: 17331

drug/chemical compound

Nebivolol

decreases_activity of

after angiotensin II treatment
Drugbank entries Show/Hide entries for Nebivolol
Comment In vivo treatment with nebivolol markedly improved endothelial dysfunction and increased P-VASP levels in Ang II-treated animals, while having no effects on these parameters in control animals. Metoprolol had no significant effects on these parameters.
Formal Description
Interaction-ID: 17332

drug/chemical compound

Metoprolol

NOT decreases_activity of

after angiotensin II treatment
Drugbank entries Show/Hide entries for Metoprolol
Comment In vivo treatment with nebivolol markedly improved endothelial dysfunction and increased P-VASP levels in Ang II-treated animals, while having no effects on these parameters in control animals. Metoprolol had no significant effects on these parameters.
Formal Description
Interaction-ID: 17333

drug/chemical compound

Nebivolol

increases_phosphorylation of

gene/protein

VASP

after angiotensin II treatment
Drugbank entries Show/Hide entries for Nebivolol
Comment In vivo treatment with nebivolol markedly improved endothelial dysfunction and increased P-VASP levels in Ang II-treated animals, while having no effects on these parameters in control animals. Metoprolol had no significant effects on these parameters.
Formal Description
Interaction-ID: 17334

drug/chemical compound

Metoprolol

NOT increases_phosphorylation of

gene/protein

VASP

after angiotensin II treatment
Drugbank entries Show/Hide entries for Metoprolol
Comment Ang II infusion also slightly but significantly decreased potency of the endothelium-independent vasodilator nitroglycerin, which was not corrected by nebivolol treatment.
Formal Description
Interaction-ID: 17335

gene/protein

Angiotensin II

decreases_activity of

drug/chemical compound

Nitroglycerin

Drugbank entries Show/Hide entries for
Comment Ang II infusion also slightly but significantly decreased potency of the endothelium-independent vasodilator nitroglycerin, which was not corrected by nebivolol treatment.
Formal Description
Interaction-ID: 17336

drug/chemical compound

Nebivolol

NOT affects_activity of

drug/chemical compound

Nitroglycerin

after angiotensin II treatment
Drugbank entries Show/Hide entries for Nebivolol or Nitroglycerin
Comment Treatment with the beta-receptor blocker nebivolol but not metoprolol normalized endothelial function, reduced superoxide formation, increased NO bioavailability.
Formal Description
Interaction-ID: 17340

drug/chemical compound

Nebivolol

decreases_quantity of

drug/chemical compound

O2-

after angiotensin II treatment
Drugbank entries Show/Hide entries for Nebivolol
Comment Treatment with the beta-receptor blocker nebivolol but not metoprolol normalized endothelial function, reduced superoxide formation, increased NO bioavailability.
Formal Description
Interaction-ID: 17356

drug/chemical compound

Metoprolol

NOT decreases_quantity of

drug/chemical compound

O2-

after angiotensin II treatment
Drugbank entries Show/Hide entries for Metoprolol
Comment Treatment with the beta-receptor blocker nebivolol but not metoprolol normalized endothelial function, reduced superoxide formation, increased NO bioavailability.
Formal Description
Interaction-ID: 17357

drug/chemical compound

Nebivolol

increases_quantity of

drug/chemical compound

NO

after angiotensin II treatment
Drugbank entries Show/Hide entries for Nebivolol
Comment Treatment with the beta-receptor blocker nebivolol but not metoprolol normalized endothelial function, reduced superoxide formation, increased NO bioavailability.
Formal Description
Interaction-ID: 17358

drug/chemical compound

Metoprolol

NOT increases_quantity of

drug/chemical compound

NO

after angiotensin II treatment
Drugbank entries Show/Hide entries for Metoprolol
Comment Ang II treatment upregulated the expression of p67phox and Rac1 in aortic membrane fractions and in heart membranes, all of which was normalized by in vivo nebivolol treatment. In addition, there were significant increases in the expression of Nox1 in heart membranes that were decreased by treatment with nebivolol. Significant increases in Nox2 (gp91phox), p47phox, and p22phox mRNA were found in aortic and heart tissue ranging from 2- to 4-fold, all of which were almost normalized by nebivolol but not metoprolol cotreatment in vivo.
Formal Description
Interaction-ID: 17359

gene/protein

Angiotensin II

increases_expression of

gene/protein

NCF2

in membranes, in aorta, in cardiac muscle
Comment Ang II treatment upregulated the expression of p67phox and Rac1 in aortic membrane fractions and in heart membranes, all of which was normalized by in vivo nebivolol treatment. In addition, there were significant increases in the expression of Nox1 in heart membranes that were decreased by treatment with nebivolol. Significant increases in Nox2 (gp91phox), p47phox, and p22phox mRNA were found in aortic and heart tissue ranging from 2- to 4-fold, all of which were almost normalized by nebivolol but not metoprolol cotreatment in vivo.
Formal Description
Interaction-ID: 17360

gene/protein

Angiotensin II

increases_expression of

gene/protein

RAC1

in membranes, in aorta, in cardiac muscle
Drugbank entries Show/Hide entries for RAC1
Comment Ang II treatment upregulated the expression of p67phox and Rac1 in aortic membrane fractions and in heart membranes, all of which was normalized by in vivo nebivolol treatment. In addition, there were significant increases in the expression of Nox1 in heart membranes that were decreased by treatment with nebivolol. Significant increases in Nox2 (gp91phox), p47phox, and p22phox mRNA were found in aortic and heart tissue ranging from 2- to 4-fold, all of which were almost normalized by nebivolol but not metoprolol cotreatment in vivo.
Formal Description
Interaction-ID: 17361

drug/chemical compound

Nebivolol

decreases_expression of

gene/protein

NCF2

in membranes, in aorta, in cardiac muscle; after angiotensin II treatment
Drugbank entries Show/Hide entries for Nebivolol
Comment Ang II treatment upregulated the expression of p67phox and Rac1 in aortic membrane fractions and in heart membranes, all of which was normalized by in vivo nebivolol treatment. In addition, there were significant increases in the expression of Nox1 in heart membranes that were decreased by treatment with nebivolol. Significant increases in Nox2 (gp91phox), p47phox, and p22phox mRNA were found in aortic and heart tissue ranging from 2- to 4-fold, all of which were almost normalized by nebivolol but not metoprolol cotreatment in vivo.
Formal Description
Interaction-ID: 17362

drug/chemical compound

Nebivolol

decreases_expression of

gene/protein

RAC1

in membranes, in aorta, in cardiac muscle; after angiotensin II treatment
Drugbank entries Show/Hide entries for Nebivolol or RAC1
Comment Ang II treatment upregulated the expression of p67phox and Rac1 in aortic membrane fractions and in heart membranes, all of which was normalized by in vivo nebivolol treatment. In addition, there were significant increases in the expression of Nox1 in heart membranes that were decreased by treatment with nebivolol. Significant increases in Nox2 (gp91phox), p47phox, and p22phox mRNA were found in aortic and heart tissue ranging from 2- to 4-fold, all of which were almost normalized by nebivolol but not metoprolol cotreatment in vivo.
Formal Description
Interaction-ID: 17363

gene/protein

Angiotensin II

increases_expression of

gene/protein

NOX1

in membranes, in cardiac muscle
Comment Ang II treatment upregulated the expression of p67phox and Rac1 in aortic membrane fractions and in heart membranes, all of which was normalized by in vivo nebivolol treatment. In addition, there were significant increases in the expression of Nox1 in heart membranes that were decreased by treatment with nebivolol. Significant increases in Nox2 (gp91phox), p47phox, and p22phox mRNA were found in aortic and heart tissue ranging from 2- to 4-fold, all of which were almost normalized by nebivolol but not metoprolol cotreatment in vivo.
Formal Description
Interaction-ID: 17364

drug/chemical compound

Nebivolol

decreases_expression of

gene/protein

NOX1

in membranes, in cardiac muscle; after angiotensin II treatment
Drugbank entries Show/Hide entries for Nebivolol
Comment Ang II treatment upregulated the expression of p67phox and Rac1 in aortic membrane fractions and in heart membranes, all of which was normalized by in vivo nebivolol treatment. In addition, there were significant increases in the expression of Nox1 in heart membranes that were decreased by treatment with nebivolol. Significant increases in Nox2 (gp91phox), p47phox, and p22phox mRNA were found in aortic and heart tissue ranging from 2- to 4-fold, all of which were almost normalized by nebivolol but not metoprolol cotreatment in vivo.
Formal Description
Interaction-ID: 17365

gene/protein

Angiotensin II

increases_expression of

gene/protein

CYBB

in aorta, in cardiac muscle
Comment Ang II treatment upregulated the expression of p67phox and Rac1 in aortic membrane fractions and in heart membranes, all of which was normalized by in vivo nebivolol treatment. In addition, there were significant increases in the expression of Nox1 in heart membranes that were decreased by treatment with nebivolol. Significant increases in Nox2 (gp91phox), p47phox, and p22phox mRNA were found in aortic and heart tissue ranging from 2- to 4-fold, all of which were almost normalized by nebivolol but not metoprolol cotreatment in vivo.
Formal Description
Interaction-ID: 17366

gene/protein

Angiotensin II

increases_expression of

gene/protein

NCF1

in aorta, in cardiac muscle
Comment Ang II treatment upregulated the expression of p67phox and Rac1 in aortic membrane fractions and in heart membranes, all of which was normalized by in vivo nebivolol treatment. In addition, there were significant increases in the expression of Nox1 in heart membranes that were decreased by treatment with nebivolol. Significant increases in Nox2 (gp91phox), p47phox, and p22phox mRNA were found in aortic and heart tissue ranging from 2- to 4-fold, all of which were almost normalized by nebivolol but not metoprolol cotreatment in vivo.
Formal Description
Interaction-ID: 17367

gene/protein

Angiotensin II

increases_expression of

gene/protein

CYBA

in aorta, in cardiac muscle
Comment Ang II treatment upregulated the expression of p67phox and Rac1 in aortic membrane fractions and in heart membranes, all of which was normalized by in vivo nebivolol treatment. In addition, there were significant increases in the expression of Nox1 in heart membranes that were decreased by treatment with nebivolol. Significant increases in Nox2 (gp91phox), p47phox, and p22phox mRNA were found in aortic and heart tissue ranging from 2- to 4-fold, all of which were almost normalized by nebivolol but not metoprolol cotreatment in vivo.
Formal Description
Interaction-ID: 17368

drug/chemical compound

Nebivolol

decreases_expression of

gene/protein

CYBB

in aorta, in cardiac muscle; after angiotensin II treatment
Drugbank entries Show/Hide entries for Nebivolol
Comment Ang II treatment upregulated the expression of p67phox and Rac1 in aortic membrane fractions and in heart membranes, all of which was normalized by in vivo nebivolol treatment. In addition, there were significant increases in the expression of Nox1 in heart membranes that were decreased by treatment with nebivolol. Significant increases in Nox2 (gp91phox), p47phox, and p22phox mRNA were found in aortic and heart tissue ranging from 2- to 4-fold, all of which were almost normalized by nebivolol but not metoprolol cotreatment in vivo.
Formal Description
Interaction-ID: 17369

drug/chemical compound

Nebivolol

decreases_expression of

gene/protein

NCF1

in aorta, in cardiac muscle; after angiotensin II treatment
Drugbank entries Show/Hide entries for Nebivolol
Comment Ang II treatment upregulated the expression of p67phox and Rac1 in aortic membrane fractions and in heart membranes, all of which was normalized by in vivo nebivolol treatment. In addition, there were significant increases in the expression of Nox1 in heart membranes that were decreased by treatment with nebivolol. Significant increases in Nox2 (gp91phox), p47phox, and p22phox mRNA were found in aortic and heart tissue ranging from 2- to 4-fold, all of which were almost normalized by nebivolol but not metoprolol cotreatment in vivo.
Formal Description
Interaction-ID: 17370

drug/chemical compound

Nebivolol

decreases_expression of

gene/protein

CYBA

in aorta, in cardiac muscle; after angiotensin II treatment
Drugbank entries Show/Hide entries for Nebivolol
Comment Ang II treatment upregulated the expression of p67phox and Rac1 in aortic membrane fractions and in heart membranes, all of which was normalized by in vivo nebivolol treatment. In addition, there were significant increases in the expression of Nox1 in heart membranes that were decreased by treatment with nebivolol. Significant increases in Nox2 (gp91phox), p47phox, and p22phox mRNA were found in aortic and heart tissue ranging from 2- to 4-fold, all of which were almost normalized by nebivolol but not metoprolol cotreatment in vivo.
Formal Description
Interaction-ID: 17371

drug/chemical compound

Metoprolol

NOT decreases_expression of

gene/protein

CYBB

in aorta, in cardiac muscle; after angiotensin II treatment
Drugbank entries Show/Hide entries for Metoprolol
Comment Ang II treatment upregulated the expression of p67phox and Rac1 in aortic membrane fractions and in heart membranes, all of which was normalized by in vivo nebivolol treatment. In addition, there were significant increases in the expression of Nox1 in heart membranes that were decreased by treatment with nebivolol. Significant increases in Nox2 (gp91phox), p47phox, and p22phox mRNA were found in aortic and heart tissue ranging from 2- to 4-fold, all of which were almost normalized by nebivolol but not metoprolol cotreatment in vivo.
Formal Description
Interaction-ID: 17372

drug/chemical compound

Metoprolol

NOT decreases_expression of

gene/protein

NCF1

in aorta, in cardiac muscle; after angiotensin II treatment
Drugbank entries Show/Hide entries for Metoprolol
Comment Ang II treatment upregulated the expression of p67phox and Rac1 in aortic membrane fractions and in heart membranes, all of which was normalized by in vivo nebivolol treatment. In addition, there were significant increases in the expression of Nox1 in heart membranes that were decreased by treatment with nebivolol. Significant increases in Nox2 (gp91phox), p47phox, and p22phox mRNA were found in aortic and heart tissue ranging from 2- to 4-fold, all of which were almost normalized by nebivolol but not metoprolol cotreatment in vivo.
Formal Description
Interaction-ID: 17373

drug/chemical compound

Metoprolol

NOT decreases_expression of

gene/protein

CYBA

in aorta, in cardiac muscle; after angiotensin II treatment
Drugbank entries Show/Hide entries for Metoprolol
Comment Vascular NADPH oxidase activity, as well as expression at the mRNA and protein level, were markedly upregulated in Ang II-treated animals, superoxide production (NADPH oxidase activity) in heart membranes of Ang II-treated animals was concentration-dependently inhibited by nebivolol. With respect to other beta-blockers, carvedilol but not atenolol and metoprolol were able to inhibit superoxide production to a similar extent.
Formal Description
Interaction-ID: 17375

gene/protein

Angiotensin II

increases_activity of

complex/PPI

NADPH oxidase complex

Comment Vascular NADPH oxidase activity, as well as expression at the mRNA and protein level, were markedly upregulated in Ang II-treated animals, superoxide production (NADPH oxidase activity) in heart membranes of Ang II-treated animals was concentration-dependently inhibited by nebivolol. With respect to other beta-blockers, carvedilol but not atenolol and metoprolol were able to inhibit superoxide production to a similar extent.
Formal Description
Interaction-ID: 17376

drug/chemical compound

Nebivolol

decreases_activity of

complex/PPI

NADPH oxidase complex

after angiotensin II treatment
Drugbank entries Show/Hide entries for Nebivolol
Comment Vascular NADPH oxidase activity, as well as expression at the mRNA and protein level, were markedly upregulated in Ang II-treated animals, superoxide production (NADPH oxidase activity) in heart membranes of Ang II-treated animals was concentration-dependently inhibited by nebivolol. With respect to other beta-blockers, carvedilol but not atenolol and metoprolol were able to inhibit superoxide production to a similar extent.
Formal Description
Interaction-ID: 17377

drug/chemical compound

Carvedilol

decreases_activity of

complex/PPI

NADPH oxidase complex

after angiotensin II treatment
Drugbank entries Show/Hide entries for Carvedilol
Comment Vascular NADPH oxidase activity, as well as expression at the mRNA and protein level, were markedly upregulated in Ang II-treated animals, superoxide production (NADPH oxidase activity) in heart membranes of Ang II-treated animals was concentration-dependently inhibited by nebivolol. With respect to other beta-blockers, carvedilol but not atenolol and metoprolol were able to inhibit superoxide production to a similar extent.
Formal Description
Interaction-ID: 17379

drug/chemical compound

Atenolol

NOT decreases_activity of

complex/PPI

NADPH oxidase complex

after angiotensin II treatment
Drugbank entries Show/Hide entries for Atenolol
Comment Vascular NADPH oxidase activity, as well as expression at the mRNA and protein level, were markedly upregulated in Ang II-treated animals, superoxide production (NADPH oxidase activity) in heart membranes of Ang II-treated animals was concentration-dependently inhibited by nebivolol. With respect to other beta-blockers, carvedilol but not atenolol and metoprolol were able to inhibit superoxide production to a similar extent.
Formal Description
Interaction-ID: 17380

drug/chemical compound

Metoprolol

NOT decreases_activity of

complex/PPI

NADPH oxidase complex

after angiotensin II treatment
Drugbank entries Show/Hide entries for Metoprolol
Comment The novel beta1-receptor blocker nebivolol but not metoprolol prevents Ang II induced NOS III uncoupling.
Formal Description
Interaction-ID: 17386

gene/protein

Angiotensin II

decreases_activity of

gene/protein

NOS3

via uncoupling of the active homodimer
Drugbank entries Show/Hide entries for NOS3
Comment The novel beta1-receptor blocker nebivolol but not metoprolol prevents Ang II induced NOS III uncoupling.
Formal Description
Interaction-ID: 17387

drug/chemical compound

Nebivolol

NOT decreases_activity of

gene/protein

NOS3

after angiotensin II treatment
Drugbank entries Show/Hide entries for Nebivolol or NOS3